Date: 2011-04-12
Type of information: Licensing agreement
Compound: A2A receptor antagonist programme
Company: Vernalis (UK) Biogen Idec (USA)
Therapeutic area: Neurodegenerative diseases - CNS diseases
Type agreement: licensing
development
commercialisation
Action mechanism:
Disease: Parkinson's disease and other neurological disorders
Details: Vernalis has successfully regained rights to the next generation A2A receptor antagonist programme for Parkinson’s disease and potentially other neurological disorders from Biogen Idec. The lead molecule, V81444, is Phase I ready, having received MHRA approval for first dosing in man. A separate announcement will be made when the first subject has been dosed in this Phase I study which will be in healthy volunteers and designed to assess the safety, tolerability and pharmacokinetic profiles.
Financial terms:
Latest news:
